🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

Revvity, Inc. RVTY SPX

Healthcare · Diagnostics & Research · United States
https://www.revvity.com

Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray , EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

READ MORE ›
$104.55
+15.96% 1Y

Market & Price

Market Cap
$11.66B
Current Price
$104.55
High / Low (52W)
$117.66 / $82.26
Beta
1.05

Valuation

Stock P/E
50.26
Industry PE
23.65
Forward P/E
17.99
PEG Ratio
0.64
Book Value
$64.20
Price to Book
1.63
P/S
4.02
EV/EBITDA
16.55
Dividend Yield
0.27%

Profitability & Returns

ROCE
3.33%
ROE
3.23%
ROA
2.27%
Profit Margin
8.26%
Op Margin
12.35%
EPS (Latest Qtr)
$0.36
EPS (TTM)
$2.08

Balance Sheet & Liquidity

Debt/Equity
0.47
Quick Ratio
1.25
Current Ratio
1.72
Debt
$3.35B
Total Assets
$12.17B
Current Assets
$2.24B
Working Capital
$908.50M

Ownership

Promoter Holding
0.36%
Chg in Prom Hold
-
FII / Inst Holding
105.75%
Chg in FII Hold
-0.00%

Financial Snapshot

Enterprise Value
$14.15B
Total Revenue (TTM)
$2.90B
EBITDA
$855.24M
Free Cash Flow
$508.97M
Operating Cash Flow
$570.01M
Shares Outstanding
111.56M
Gross Margin
54.32%
Payout Ratio
13.46%

Growth (CAGR)

Revenue 5Y
-4.82%
Profit 5Y
-24.89%
Revenue (YoY)
7.00%
Earnings (YoY)
3.50%

PROS

  • Generates positive free cash flow.

CONS

  • Trading at a high P/E of 50.3.
  • Revenue declined at -4.8% CAGR over 5 years.
  • Earnings shrank at -24.9% CAGR over 5 years.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 RVTY Revvity, Inc. SPX 104.55 50.26 $11.66B 0.27% 3.33% 3.23% -4.82% -24.89%
2 LLY Eli Lilly and Company SPX 1,105.00 39.21 $985.37B 0.63% 38.44% 107.46% 31.69% 48.96%
3 JNJ Johnson & Johnson SPX 225.33 26.11 $542.42B 2.38% 23.13% 26.42% 5.60% 14.32%
4 UNH UnitedHealth Group Incorporated SPX 380.31 28.66 $345.38B 2.32% 9.60% 12.18% 11.35% -15.69%
5 MRK Merck & Co., Inc. SPX 118.72 33.44 $293.22B 2.86% 20.66% 18.94% 3.12% 7.93%
6 TMO Thermo Fisher Scientific Inc. SPX 492.51 27.11 $183.03B 0.38% 9.17% 13.52% -0.27% -1.19%
7 AMGN Amgen Inc. NDXSPX 336.79 23.42 $181.77B 2.99% 18.02% 101.32% 11.77% 5.58%
8 GILD Gilead Sciences, Inc. NDXSPX 134.43 18.29 $166.90B 2.44% 22.92% 43.36% 2.57% 22.83%
9 ISRG Intuitive Surgical, Inc. NDXSPXAI 424.64 51.53 $150.39B - 15.96% 17.23% 17.39% 29.26%
Ad space

Quarterly Results

Figures in USD.

Metric Apr 2016Jul 2016Oct 2016Jan 2017Apr 2017Jul 2017Oct 2017Dec 2017Apr 2018Jul 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Apr 2020Jul 2020Oct 2020Jan 2021Apr 2021Jul 2021Oct 2021Jan 2022Apr 2022Jul 2022Oct 2022Jan 2023Apr 2023Jul 2023Oct 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Apr 2026
Revenue -----546.96M554.27M-643.97M703.36M674.31M-648.74M722.52M706.92M-652.40M811.72M964.02M-1.31B1.23B861.32M-963.16M895.64M711.80M-674.87M709.07M670.74M649.92M691.68M-664.76M720.28M698.95M772.06M711.12M711.12M
Cost of Revenue ----------------------------------289.22M327.73M324.35M350.40M323.46M-
Gross Profit 235.09M253.55M248.55M276.16M239.76M257.60M268.97M307.43M292.22M340.14M332.33M376.25M307.81M347.79M342.27M398.18M308.02M447.34M527.45M827.07M693.19M574.14M522.86M643.80M594.74M551.72M407.04M436.33M------375.55M392.56M374.60M421.66M387.65M-
Operating Expenses ----------------------------------303.32M303.49M292.71M309.91M311.77M-
Operating Income 60.58M66.27M75.78M80.44M49.81M74.18M78.04M93.58M39.94M88.06M80.20M115.68M53.33M91.73M78.66M138.25M44.68M175.64M248.01M510.25M455.01M308.00M195.55M299.89M261.96M232.49M110.78M137.47M76.12M78.06M69.23M44.12M85.72M-72.23M89.06M81.90M111.75M75.89M75.89M
EBITDA ----------------------------------172.77M194.37M180.52M218.15M179.77M-
Interest Expense ----------------------------------22.96M22.94M22.77M23.51M24.72M-
Pretax Income ----------------------------------52.38M68.65M55.69M91.56M49.99M-
Tax Provision ----------------------------------10.71M13.43M8.46M-4.21M9.10M-
Net Income 47.47M63.86M58.13M64.85M38.60M204.07M91.08M-41.12M26.02M64.06M76.55M71.29M35.41M69.09M58.56M64.50M33.66M137.16M176.70M380.36M379.31M245.93M127.74M190.18M176.96M179.21M85.35M127.66M569.48M35.56M9.50M26.01M55.36M-42.24M53.95M46.65M98.36M40.72M40.72M
Diluted EPS 0.430.580.530.590.351.840.82-0.370.230.570.690.640.320.620.520.580.301.231.573.383.372.191.111.501.401.420.671.014.500.280.080.210.45-0.350.460.400.870.360.36
R&D Expense 29.97M31.87M29.51M-33.29M33.56M34.88M-45.98M47.20M48.85M-47.98M48.34M45.38M-48.91M49.52M50.13M-60.22M65.82M49.42M-57.52M56.04M53.52M-56.69M57.25M53.04M50.36M48.13M49.14M53.60M53.27M50.80M--57.89M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2008Jan 2010Jan 2011Jan 2012Dec 2012Dec 2013Dec 2014Jan 2016Jan 2017Dec 2017Dec 2018Dec 2019Jan 2021Dec 2021Jan 2022Dec 2022Jan 2023Dec 2023Dec 2024Dec 2025
Revenue --------2.12B2.26B2.78B2.88B2.66B-3.83B3.31B3.31B2.75B2.76B2.86B
Cost of Revenue ---------------1.32B-1.21B1.22B1.29B
Gross Profit --761.23M847.80M963.21M976.14M1.00B964.23M1.01B1.07B1.34B1.40B2.11B-2.43B1.99B1.99B1.54B1.54B1.56B
Operating Expenses ---------------1.25B-1.24B1.19B1.21B
Operating Income 147.63M115.95M157.57M91.13M103.12M227.79M165.01M250.93M294.58M295.62M323.88M361.97M867.27M-1.26B742.70M742.70M300.56M346.74M356.63M
EBITDA ---------------1.18B-713.56M840.25M765.80M
Interest Expense ---------------103.95M-98.81M96.28M92.19M
Pretax Income ---------------651.84M-182.98M316.13M268.28M
Tax Provision ---------------139.16M-3.47M33.05M28.39M
Net Income 126.41M82.08M390.98M7.66M69.94M167.21M157.78M212.43M234.30M292.63M237.93M227.56M727.89M-943.16M569.18M569.18M693.09M270.38M241.20M
Diluted EPS 1.070.703.310.070.611.471.391.872.122.642.132.046.49-8.084.584.505.552.202.07
R&D Expense 93.03M90.49M94.81M115.82M131.84M132.40M108.06M112.54M124.18M139.46M194.00M189.34M146.44M-200.34M-221.62M216.58M196.84M215.84M

Compounded Sales Growth

5 Years:-4.82%
1 Year:7.00%

Compounded Profit Growth

5 Years:-24.89%
1 Year:3.50%

Stock Price Performance

1 Year:+15.96%
6 Months:-0.83%
3 Months:+6.43%
1 Month:+27.10%

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2007Dec 2008Jan 2010Jan 2011Jan 2012Dec 2012Dec 2013Dec 2014Jan 2016Jan 2017Dec 2017Dec 2018Dec 2019Jan 2021Dec 2021Jan 2022Dec 2022Jan 2023Dec 2023Dec 2024Dec 2025
Total Assets --3.06B3.21B3.86B3.90B3.95B4.13B4.17B4.28B6.09B5.98B6.54B7.96B-15.00B14.13B14.13B13.56B12.39B12.17B
Current Assets ----------------3.29B-3.00B2.35B2.24B
Cash & Equivalents 203.35M179.11M179.71M420.09M142.34M173.24M174.82M174.82M237.93M359.26M202.13M163.11M191.88M387.05M-603.32M454.36M454.36M913.16M1.16B919.86M
Inventory ----------------405.46M-428.06M367.59M379.50M
Receivables ----------------612.78M-632.81M632.40M744.67M
Total Liabilities --1.43B1.28B2.01B1.96B1.95B2.09B2.06B2.12B3.59B3.39B3.72B4.22B-7.86B6.75B6.75B5.69B4.73B4.92B
Current Liabilities --497.20M515.20M598.68M581.10M602.80M597.31M561.49M603.36M950.90M771.63M762.83M1.65B-1.21B1.54B1.54B1.45B653.10M1.33B
Long Term Debt --558.20M424.00M944.91M938.82M932.10M1.05B1.01B1.05B1.79B1.88B2.06B1.61B-4.98B3.92B3.92B3.18B3.15B2.63B
Total Debt ----------------4.60B-4.07B3.33B3.40B
Total Equity 1.58B1.57B1.63B1.93B1.84B1.94B1.99B2.04B2.11B2.15B2.50B2.58B2.81B3.74B-7.14B7.38B7.38B7.87B7.67B7.25B
Shares Outstanding ----------------126.30M-123.43M120.65M112.28M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2008Jan 2010Jan 2011Jan 2012Dec 2012Dec 2013Dec 2014Jan 2016Jan 2017Dec 2017Dec 2018Dec 2019Jan 2021Dec 2021Jan 2022Dec 2022Jan 2023Dec 2023Dec 2024Dec 2025
Operating Cash Flow 217.84M148.72M164.25M224.87M152.17M158.59M281.60M287.10M350.62M288.45M311.04M363.47M892.18M-1.41B679.81M679.81M91.27M628.30M582.93M
Investing Cash Flow -135.68M-153.87M295.15M-909.86M-80.31M-1.21M-295.90M-100.86M-83.88M-1.27B-159.86M-487.57M-504.50M--4.11B-132.85M-132.85M1.31B776.16M-17.35M
Financing Cash Flow -101.08M2.41M-218.37M397.20M-44.16M-154.16M30.93M-107.14M-115.01M782.24M-179.23M-150.13M-202.87M-2.94B-661.80M-661.80M-947.12M-1.13B-857.52M
Capital Expenditure -35.27M-25.52M-33.65M-30.59M-42.40M-38.98M-27.15M-28.22M-31.70M-39.09M-93.25M-76.33M-63.63M--86.02M-85.63M-85.63M-81.37M-86.65M-73.52M
Free Cash Flow 182.57M123.21M130.61M194.28M109.77M119.61M254.44M258.88M318.91M249.36M217.78M287.14M828.54M-1.32B594.18M594.18M9.90M541.65M509.41M
Net Change in Cash ----------------114.84M-457.68M276.23M-291.94M
Share Buybacks 75.51M14.62M72.77M110.00M2.10M127.40M65.53M76.44M151.80M3.83M57.45M6.31M6.94M-73.07M-80.64M388.88M369.58M820.82M

Ratios (Annual)

Figures in %.

Metric Dec 2008Jan 2010Jan 2011Jan 2012Dec 2012Dec 2013Dec 2014Jan 2016Jan 2017Dec 2017Dec 2018Dec 2019Jan 2021Dec 2021Jan 2022Dec 2022Jan 2023Dec 2023Dec 2024Dec 2025
Gross Margin % --------47.9%47.6%48.3%48.4%79.2%-63.6%60.1%60.1%56.0%55.8%54.8%
Operating Margin % --------13.9%13.1%11.7%12.6%32.6%-32.9%22.4%22.4%10.9%12.6%12.5%
Net Margin % --------11.1%13.0%8.6%7.9%27.3%-24.6%17.2%17.2%25.2%9.8%8.4%
ROE % 8.1%5.0%20.3%0.4%3.6%8.4%7.7%10.1%10.9%11.7%9.2%8.1%19.5%-13.2%7.7%7.7%8.8%3.5%3.3%
ROCE % -4.5%5.8%2.8%3.1%6.8%4.7%7.0%8.0%5.8%6.2%6.3%13.7%-9.1%5.9%5.9%2.5%3.0%3.3%

Shareholding Pattern

Insiders
0.36%
Institutions
105.75%
Public Float
106.14%

Top Institutional Holders

#Holder% HeldSharesValue
1 T. Rowe Price Investment Management, Inc. 19.90% 22.20M $2.32B
2 Price (T.Rowe) Associates Inc 9.04% 10.09M $1.05B
3 Edgepoint Investment Group Inc. 7.89% 8.80M $920.13M
4 Janus Henderson Group PLC 7.48% 8.35M $872.80M
5 Vanguard Capital Management LLC 6.57% 7.33M $766.35M
6 Blackrock Inc. 6.50% 7.25M $758.03M
7 Vanguard Portfolio Management LLC 4.31% 4.81M $503.22M
8 State Street Corporation 3.86% 4.31M $450.64M
9 Victory Capital Management Inc. 3.02% 3.37M $352.61M
10 Geode Capital Management, LLC 2.63% 2.94M $307.08M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for RVTY

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks